There are 413 resources available
Future directions for ADCs
Presenter: Javier Cortes
Session: HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers
Resources:
Slides
Webcast
Role of germline genetic testing in early breast cancer for therapeutic purposes
Presenter: Soo Chin Lee
Session: From familial to theranostic germline genetics in breast cancer
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Mini Oral session 1
Resources:
Webcast
What’s on the horizon for immunotherapy for TNBC?
Presenter: Giampaolo Bianchini
Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers
Resources:
Webcast
Q&A and discussion
Presenter: To be Announced
Session: From familial to theranostic germline genetics in breast cancer
Resources:
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Refining checkpoint inhibition in triple-negative breast cancer (TNBC)
Resources:
Webcast
190MO - Association of 18-Gene Expression Profile (GEP) With Clinical Outcomes in Patients With Metastatic Triple-Negative Breast Cancer (mTNBC) Treated With Pembrolizumab (Pembro) or Chemotherapy (Chemo) in KEYNOTE-119
Presenter: Peter Schmid
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
191MO - KEYNOTE-355: Outcomes in patients who discontinued chemotherapy before pembrolizumab and in patients with immune-mediated AEs
Presenter: Hope Rugo
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast
1MO - Tumor immune microenvironment in ER-negative vs. ER-low, HER2-neg breast cancer
Presenter: Davide Massa
Session: Mini Oral session 1
Resources:
Abstract
Slides
Webcast